Exponent (EXPO) Earnings: Q3 Fiscal 2026 Results

The quarter ended October 2, 2026 and Exponent published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 fiscal 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Revenue here is Exponent's total "Revenues" line, which includes reimbursements. Exponent's own headline measure, and the basis of its guidance, is revenues before reimbursements: $153.1 million in Q3 fiscal 2026, against $137.1 million. Exponent reports in thousands; figures here are in millions.
• Exponent's fiscal quarters end on a Friday: Q3 fiscal 2026 ended October 2, 2026 and Q3 fiscal 2025 ended October 3, 2025. It reports one EPS figure, on a GAAP basis.

Source: Exponent Q3 fiscal 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended October 2, 2026. Figures as reported; checked against the release on November 10, 2026.

How Exponent splits revenue in its own release, under its own labels, for Q3 fiscal 2026 against Q3 fiscal 2025. Indented lines are parts of the line above them.

• Exponent's Engineering and Other Scientific revenue was $150 million in Q3 fiscal 2026, up 21% from $124 million in Q3 fiscal 2025, 86% of total revenue.
• Exponent's Environmental and Health revenue was $23.6 million in Q3 fiscal 2026, up 2% from $23.1 million in Q3 fiscal 2025, 14% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 fiscal 2026 release, Exponent said:

“For the fourth quarter of fiscal 2026 as compared to the same period one year prior, Exponent anticipates: Revenues before reimbursements to grow 8% to 10%;”

“For the full fiscal year 2026 as compared to fiscal year 2025, Exponent anticipates: Revenues before reimbursements to grow 10% to 11%;”

Source: Exponent Q3 fiscal 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the EXPO forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues (including reimbursements) and diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for Exponent's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 fiscal 2026 (this page), reported Oct 29, 2026

Exponent's total revenues were $173.7 million in Q3 fiscal 2026, up 18% from $147.1 million. Revenues before reimbursements, the measure Exponent leads with, rose 12% to $153.1 million. Reimbursements more than doubled to $20.7 million from $10.0 million, and the 10-Q links part of that to user research projects. (Exponent Q3 fiscal 2026 release, Oct 29, 2026; Exponent Form 10-Q, Q3 fiscal 2026, Nov 6, 2026)

Exponent has two segments. Engineering and Other Scientific brought in $150.1 million of total revenues, 86.4% of the total, and grew 21.0%. Environmental and Health brought in $23.6 million, up 2.3%. On a revenues-before-reimbursements basis the split was 85% and 15%. (Exponent Form 10-Q, Q3 fiscal 2026, Nov 6, 2026; Exponent Q3 fiscal 2026 release, Oct 29, 2026)

Exponent sells consultants' time, so revenue moves with hours and rates. Billable hours rose 8% to 405,000, utilization rose to 77% from 74%, and average technical full-time equivalent employees rose 4% to 1,016. The 10-Q attributes Engineering and Other Scientific growth to more billable hours, higher billing rates and reimbursements on user research projects. (Exponent Form 10-Q, Q3 fiscal 2026, Nov 6, 2026)

By Exponent's account, growth in the quarter came from user research studies in consumer electronics and reactive, dispute-related and failure analysis work in the chemical, consumer products and transportation industries. Environmental and Health growth came from projects assessing the effects of chemicals on human health and the environment. (Exponent Q3 fiscal 2026 release, Oct 29, 2026; Exponent Form 10-Q, Q3 fiscal 2026, Nov 6, 2026)

Exponent's diluted EPS rose to $0.64 in Q3 fiscal 2026 from $0.55, on net income of $30.9 million against $28.0 million. Operating income grew faster, to $41.9 million from $29.0 million, but other income fell to $1.1 million from $9.6 million. (Exponent Q3 fiscal 2026 release, Oct 29, 2026)

Most of that drop in other income comes from Exponent's deferred compensation plan. Changes in the value of the plan's assets are booked as miscellaneous income and offset in compensation expense, so the Q3 fiscal 2025 gain of $7,005,000 inflated both lines a year earlier, against $159,000 this quarter. Interest income also fell, to $668 thousand, on lower cash balances. (Exponent Form 10-Q, Q3 fiscal 2026, Nov 6, 2026; Exponent Q3 fiscal 2026 release, Oct 29, 2026)

Buybacks lowered the share count: diluted shares were 48,422 thousand, against 51,179 thousand. Exponent repurchased $146.1 million of stock and paid $46.1 million in dividends in the first three quarters of 2026. Its tax rate was 28.0%, against 27.4%. (Exponent Q3 fiscal 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Exponent gives a growth outlook in its release, on revenues before reimbursements and EBITDA margin. For Q4 fiscal 2026 it expects revenues before reimbursements to grow 8% to 10% and EBITDA of 26.3% to 26.8% of revenues before reimbursements. (Exponent Q3 fiscal 2026 release, Oct 29, 2026)

Exponent raised its full fiscal year 2026 outlook and now expects revenues before reimbursements to grow 10% to 11% over fiscal 2025, with EBITDA of 28.0% to 28.3% of revenues before reimbursements. It does not give EPS guidance. (Exponent Q3 fiscal 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover Exponent, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Exponent's own release and filings put weight on for Q3 fiscal 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning EXPO is on is EXPO a buy or a sell?, what analysts expect next is on the EXPO forecast, and what the company does is on the Exponent (EXPO) stock page.

Every number on this page can be traced to a document Exponent published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.